FIIN-2 is primarily used in research settings to study and inhibit fibroblast growth factor receptors (FGFRs). Its application is significant in understanding the role of FGFR signaling pathways in various biological processes and diseases. Researchers utilize FIIN-2 to investigate its potential in targeting cancers that are driven by FGFR mutations or amplifications, as these receptors play a critical role in cell proliferation, survival, and differentiation. Additionally, FIIN-2 is employed in preclinical studies to evaluate its efficacy and selectivity in blocking FGFR activity, providing insights into the development of targeted therapies for FGFR-dependent malignancies. Its use also extends to exploring mechanisms of drug resistance and identifying combination treatment strategies to enhance therapeutic outcomes.